TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today ...

TURKU, FI / ACCESS Newswire / July 1, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today ...

TURKU, FI / ACCESS Newswire / March 2, 2026 / Faron Pharmaceuticals Ltd (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, ...

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...

A special feature for World Cancer Day 2025, highlighting the groundbreaking work of small biotech companies like Faron Pharmaceuticals in revolutionizing cancer care. Every year, World Cancer Day ...

Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen talked with Proactive's Stephen Gunnion about the company’s planned €40 million rights offering and the next development stage for its ...

Hello, everyone. My name is Juho Jalkanen. I'm the CEO of Faron Pharmaceuticals. Welcome to a very important business update. On to the next slide and to the next. A lot has been going on during the ...

The Annual Report 2025 published did not contain the auditor's report. This has been corrected in this version. TURKU, FINLAND / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE ...

TURKU, FINLAND / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), announces a correction to the company ...

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today published the ...